Novel Desensitization Kidney Transplantation

Exclusion Criteria

• •Patient with significant neuropathy by the Common Terminology Criteria for Adverse Events (CTCAE) criteria within 14 days before enrollment (Grades 3-4 or Grade 2 with pain)
• •Myocardial infarction within 6 months of enrollment or has Heart Failure in acute dialysis quality initiative (ADQI) ESRD classification system Class 2 non restrictive (2NR) or greater, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or ECG evidence of acute ischemia or active conduction system abnormalities
• •Patient who received other investigational drugs within 14 days prior to initiation of study treatment
• •Receipt of a live vaccine within 4 weeks prior to initiation of study treatment
• •Evidence of severe liver disease by history or physical exam or with abnormal liver profile ( \> 1.5 times upper limit of normal within 30 days of consent)
• •Female who is breast feeding or pregnant
• •Untreated latent tuberculosis
• •History of Post Transplant Lymphoproliferative Disease (PTLD)
• •Patient still carrying previous kidney transplant.